URGN vs WRB · rev $123.4M vs P/E 17, rev $3.72B
UroGen Pharma Ltd (URGN) versus W. R. Berkley Corp (WRB) — a side-by-side from cached financials, not a winner call.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
W. R. Berkley Corp (WRB) is a insurance - property & casualty company listed on US.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
Latest reported WRB revenue for 2026-06-30 was $3.72B. Net income was $452.3M. Revenue was up 0.7% from 2026-03-31 to 2026-06-30. WRB currently screens at market cap $27.12B and trailing P/E 16.6.
URGN currently screens at market cap $1.61B. WRB currently screens at market cap $27.12B and trailing P/E 16.6.
Not investment advice. Open the URGN and WRB stock pages for the full models.
Not investment advice.